809
Views
18
CrossRef citations to date
0
Altmetric
Reviews

Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma

, , , &
Pages 294-311 | Accepted 03 Dec 2015, Published online: 27 Apr 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Corrado Pelaia, Alessandro Vatrella, Andrea Bruni, Rosa Terracciano & Girolamo Pelaia. (2018) Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Design, Development and Therapy 12, pages 619-628.
Read now
Tara Vinyette Saco, Amber N. Pepper & Richard F. Lockey. (2017) Benralizumab for the treatment of asthma. Expert Review of Clinical Immunology 13:5, pages 405-413.
Read now

Articles from other publishers (16)

A. Yu. Kraposhina, E. A. Sobko, I. V. Demko, A. B. Katser, O. V. Kazmerchuk, Yu. I. Abramov & S. V. Chubarova. (2022) New options for severe asthma. Meditsinskiy sovet = Medical Council 16:18, pages 20-28.
Crossref
Aşkın Gülşen. 2022. Recent Advances in Asthma Research and Treatments. Recent Advances in Asthma Research and Treatments.
Mona Sadeghalvad & Nima Rezaei. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity 481 493 .
Mona Sadeghalvad & Nima Rezaei. 2021. Monoclonal Antibodies. Monoclonal Antibodies.
L. Brussino, E. Heffler, C. Bucca, S. Nicola & G. Rolla. (2018) Eosinophils Target Therapy for Severe Asthma: Critical Points. BioMed Research International 2018, pages 1-6.
Crossref
Mahsa Eskian, MirHojjat Khorasanizadeh, Amal H. Assa’ad & Nima Rezaei. (2017) Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis. Clinical Reviews in Allergy & Immunology 55:1, pages 88-98.
Crossref
Peter J. Barnes. (2018) Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology 18:7, pages 454-466.
Crossref
Ting Liu, Faping Wang, Geng Wang & Hui Mao. (2017) Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Frontiers of Medicine 12:3, pages 340-349.
Crossref
Corrado Pelaia, Cecilia Calabrese, Alessandro Vatrella, Maria Teresa Busceti, Eugenio Garofalo, Nicola Lombardo, Rosa Terracciano & Girolamo Pelaia. (2018) Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International 2018, pages 1-9.
Crossref
Tsutomu Yanagibashi, Mitsuo Satoh, Yoshinori Nagai, Masamichi Koike & Kiyoshi Takatsu. (2017) Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5. Cytokine 98, pages 59-70.
Crossref
Marie-Chantal Larose, Anne-Sophie Archambault, Véronique Provost, Michel Laviolette & Nicolas Flamand. (2017) Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma. Frontiers in Medicine 4.
Crossref
Amber N. Pepper, Harald Renz, Thomas B. Casale & Holger Garn. (2017) Biologic Therapy and Novel Molecular Targets of Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice 5:4, pages 909-916.
Crossref
MirHojjat Khorasanizadeh, Mahsa Eskian, Erwin W. Gelfand & Nima Rezaei. (2017) Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacology & Therapeutics 174, pages 112-126.
Crossref
Lisa M. Sedger, Charani Ranasinghe, Michael F. McDermott & Parisa Asvadi. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Yuehui Liu, Xinhua Zhu & Hao Zhang. (2017) Effects of chemokine receptor 3 gene silencing by RNA interference on eosinophils. Experimental and Therapeutic Medicine 13:1, pages 215-221.
Crossref
Peter J. Barnes. (2017) COUNTERPOINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? No. Chest 151:1, pages 17-20.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.